Caption Management, LLC Cel Sci Corp Call Options Transaction History

Caption Management, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2021 Nov 12, 2021	SELL	$7.64 - $12.49 $477,500 - $780,625	-62,500 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$8.68 - $27.49 $694,400 - $2.2 Million	-80,000 Reduced 56.14%	62,500 $542,000
Q1 2021 May 17, 2021	BUY	$12.0 - $27.64 $1.17 Million - $2.69 Million	97,500 Added 216.67%	142,500 $2.17 Million
Q4 2020 Feb 16, 2021	SELL	$11.05 - $16.62 $984,555 - $1.48 Million	-89,100 Reduced 66.44%	45,000 $525,000
Q3 2020 Nov 16, 2020	BUY	$11.69 - $14.54 $485,135 - $603,410	41,500 Added 44.82%	134,100 $1.71 Million
Q2 2020 Aug 14, 2020	BUY	$9.75 - $17.6 $902,850 - $1.63 Million	92,600 New	92,600 $1.38 Million

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $33.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.